New whipworm drug could beat standard treatment in one dose
NCT ID NCT07258173
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study compares a single dose of emodepside to a single dose of albendazole (the usual treatment) in 100 adolescents and adults infected with a type of whipworm. The goal is to see which drug cures more infections and reduces egg counts. Participants provide stool samples before and 14-21 days after treatment to measure success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- emodepside
- What this could lead to
- If successful, this could offer a new single-dose treatment for whipworm infections that is more effective than the current standard.
- What could go wrong
- This is a small Phase 2 trial with only 100 participants, so results may not apply broadly. The drug may not prove superior or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICHURIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.